SFTPD and bronchopulmonary dysplasia: A full-length recombinant form of human SP-D, zelpultide alfa (AT-100), is currently in phase III clinical testing by Airway Therapeutics as an orphan drug for prevention of bronchopulmonary dysplasia (BPD) and minimization of resulting lung damage in preterm infants (170, 171).